| Reconciliation of Federal Statutory Income Tax Provision To Company's Actual Provision | 
 A reconciliation of the federal statutory income tax provision to our actual provision for the years ended December 31, 2024 and 2023 is as follows: 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
|   | 
 | 
 | 
2024 | 
 | 
 | 
2023 | 
 | 
 
| Pre-tax book income (loss) | 
 | 
$ | 
(4,651,205) | 
 | 
 | 
 | 
$ | 
(4,490,665) | 
 | 
 | 
 
Expected tax at 21%   | 
 | 
(976,753) | 
 | 
 | 
 | 
(943,040) | 
 | 
 | 
 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
| Permanent differences: | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
Goodwill impairment | 
 | 
45,632  | 
 | 
 | 
 | 
—  | 
 | 
 | 
 
 | 
Intangible amortization  | 
 | 
(37,003) | 
 | 
 | 
 | 
(46,373) | 
 | 
 | 
 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
Other | 
 | 
5,169  | 
 | 
 | 
 | 
6,474  | 
 | 
 | 
 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
| State taxes: | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
Current | 
 | 
22,565  | 
 | 
 | 
 | 
32,491  | 
 | 
 | 
 
 | 
Deferred | 
 | 
(234,928) | 
 | 
 | 
 | 
(264,759) | 
 | 
 | 
 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
| Other items: | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
Expired net operating losses | 
 | 
324,799  | 
 | 
 | 
 | 
—  | 
 | 
 | 
 
 | 
Federal research and development credits | 
 | 
—  | 
 | 
 | 
 | 
(84,592) | 
 | 
 | 
 
 | 
Deferred tax past year true-ups | 
 | 
(91,289) | 
 | 
 | 
 | 
(63,440) | 
 | 
 | 
 
 | 
Change in valuation allowance | 
 | 
920,794  | 
 | 
 | 
 | 
980,342  | 
 | 
 | 
 
 | 
Capitalized research and development expenses | 
 | 
—  | 
 | 
 | 
 | 
334,120  | 
 | 
 | 
 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
Other | 
 | 
43,579  | 
 | 
 | 
 | 
81,268  | 
 | 
 | 
 
| Income tax provision | 
 | 
$ | 
22,565  | 
 | 
 | 
 | 
$ | 
32,491  | 
 | 
 | 
 
  
 | 
| Schedule of Deferred Tax Assets | 
 The components of net deferred tax assets recognized in the accompanying consolidated balance sheets at December 31, 2024 and 2023 are as follows: 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
  | 
2024 | 
 | 
2023 | 
 
 | 
Net operating loss carryforwards | 
$ | 
12,025,000  | 
 | 
 | 
$ | 
10,840,000  | 
 | 
 
 | 
R&D and ITC credit carryforwards | 
396,000  | 
 | 
 | 
403,000  | 
 | 
 
 | 
Accrued expenses and other | 
267,000  | 
 | 
 | 
381,000  | 
 | 
 
 | 
Intangibles | 
370,000  | 
 | 
 | 
499,000  | 
 | 
 
 | 
Leases | 
—  | 
 | 
 | 
8,000  | 
 | 
 
 | 
Accounts receivable | 
76,000  | 
 | 
 | 
39,000  | 
 | 
 
 | 
Stock options | 
486,000  | 
 | 
 | 
450,000  | 
 | 
 
 | 
Inventory | 
279,000  | 
 | 
 | 
427,000  | 
 | 
 
 | 
Property, plant and equipment | 
578,000  | 
 | 
 | 
650,000  | 
 | 
 
 | 
Other | 
464,000  | 
 | 
 | 
323,000  | 
 | 
 
 | 
Deferred tax assets | 
14,941,000  | 
 | 
 | 
14,020,000  | 
 | 
 
 | 
Valuation allowance | 
(14,941,000) | 
 | 
 | 
(14,020,000) | 
 | 
 
 | 
Deferred tax assets, net | 
$ | 
—  | 
 | 
 | 
$ | 
—  | 
 | 
 
  
 |